Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases
NCT ID: NCT04890028
Last Updated: 2025-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
52 participants
INTERVENTIONAL
2021-12-03
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Brain MRI is the gold standard for evaluating brain metastases but has limitations in therapeutic evaluation, partially offset by PET imaging of amino acid metabolism.
Our work aims to compare the performance of PET-DOPA with standard MRI for the detection of brain metastases (≥ 5mm) in lung cancer, breast cancer and melanoma; and to characterize these lesions using dynamic acquisitions obtained with a digital PET camera with high spatial resolution. Having better knowledge of the metabolic characteristics of newly discovered brain metastases, the objective of subsequent studies will be to better assess the per- or post-therapeutic efficacy of radiotherapy and the various systemic therapies available (chemotherapy, targeted therapy, immunotherapy).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
NCT05762172
Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)
NCT02022800
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
NCT01974804
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
NCT06072807
Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA
NCT04807582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
F-DOPA PET/CT
Drug: 18 F-DOPA Radiation: F-DOPA PET CT
F-DOPA PET/CT
All subjects will be imaged
1 time injection of 2 MBq/kg of 18F-DOPA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
F-DOPA PET/CT
All subjects will be imaged
1 time injection of 2 MBq/kg of 18F-DOPA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of brain metastasis visualized on MRI, of which at least one measures 5 mm
* Age \> 18 years
* Patient has valid health insurance
* Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
Exclusion Criteria
* History of brain surgery for brain metastasis or glial tumor
* Systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6 weeks preceding the realization of DOPA PET/CT,
* New anti-tumor treatment started between the discovery of brain metastases and the performance of DOPA PET/CT
* Other concomitant cancer, or history of cancer in the 5 years preceding the performance of DOPA PET/CT
* Pregnant or lactating females
* Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian.
Disorder precluding understanding of trial information or informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Cancerologie de l'Ouest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver Morel, MD
Role: PRINCIPAL_INVESTIGATOR
Institut de Cancérologie de l'Ouest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Angers
Angers, , France
Institut de Cancerologie de l'Ouest
Angers, , France
Institut de Cancerologie de L'Ouest
Saint-Herblain, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICO-2020-28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.